New combo therapy shows promise for deadly IPF Flare-Ups
NCT ID NCT03286556
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of plasma exchange, rituximab, and intravenous immunoglobulin in 82 people with a sudden, severe worsening of idiopathic pulmonary fibrosis (IPF). The goal was to see if this treatment could improve survival compared to usual care with antibiotics and steroids. The approach targets abnormal immune activity thought to cause lung damage during these acute episodes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a combination of plasma exchange, rituximab, and intravenous immunoglobulin (IVIG)
What this could lead to
If it works, this could offer a new treatment option for sudden, life-threatening worsening of IPF, a condition with no current effective therapy.
What could go wrong
This is a Phase 2 trial with only 82 participants, so results may not apply to all patients. The treatment is intensive and carries risks like infection from immune suppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS, ACUTE FATAL FORM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor University Medical Center
Houston, Texas, 77030, United States
-
Dan Dilling
Chicago, Illinois, 60611, United States
-
Temple University Hospital
Philadelphia, Pennsylvania, 19140, United States
-
Thomas Jefferson University Medical Center
Philadelphia, Pennsylvania, 19107, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Utah Medical Center
Salt Lake City, Utah, 84112, United States